Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Alkermes(ALKS) Prnewswire·2024-04-09 11:00— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both Narcolepsy Type 2 and Idiopathic Hypersomnia — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested — — Dose-Dependent Effects and Pharmacodynamic Profile Support Advancement Into Planned Phase 2 Study — DUBLIN, April 9, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline r ...